pharma · Metastatic Pancreatic Adenocarcinoma · Primary Biliary Cholangitis
Ipsen
Ipsen is a pharma organization headquartered in Paris, FR. Primary therapeutic focus areas include Metastatic Pancreatic Adenocarcinoma, Primary Biliary Cholangitis, Episodic Migraine, Alagille Syndrome, Not applicable.
70, Rue Balard, Paris, Île-de-France 75015, FR HQ
6,584 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 70, Rue Balard, Paris, Île-de-France 75015, FR
- Employees
- 6,584
- Programs
- 27
- Drugs
- 36
- Patents
- 0
CLIN-52120-452
Approved · small molecule · Upper limb spasticity (ULS) of any aetiology (in US and France) or post- stroke ULS (in Canada)
CLIN-52120-452 for Upper limb spasticity (ULS) of any aetiology (in US and France) or post- stroke ULS (in Canada) is a Approved program (small_molecule) at Ipsen with 1 ClinicalTrials.gov record(s).
Internal code CLIN-52120-452
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ipsen
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Upper limb spasticity (ULS) of any aetiology (in US and France) or post- stroke ULS (in Canada)
- Status
- active
- Trials
- 1